Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With two novel components included in Gilead's investigational four-drug, fixed-dose combination pill for HIV, the company has a full clinical program ahead of it - but the first Phase II results offer early signs of promise

You may also be interested in...

GSK And Pfizer Join Forces In New HIV-Focused Venture

ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.

Merck's NDA For A Pill That Combines Zetia And Lipitor Is Bounced By FDA

Citing a need for more data, the agency refuses to file an NDA for a pill combining ezetimibe (Zetia) and atorvastatin (Pfizer's Lipitor).

Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla

The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts